Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Landos Biopharma, Inc. (LABP : NSDQ)
 
 • Company Description   
Landos Biopharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. Landos Biopharma Inc. is based in BLACKSBURG, Va.

Number of Employees: 46

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.69 Daily Weekly Monthly
20 Day Moving Average: 134,989 shares
Shares Outstanding: 40.26 (millions)
Market Capitalization: $27.82 (millions)
Beta: 1.49
52 Week High: $16.17
52 Week Low: $0.61
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -37.74% -29.87%
12 Week -66.29% -62.94%
Year To Date -85.60% -82.41%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1800 KRAFT DRIVE SUITE 216
-
BLACKSBURG,VA 24060
USA
ph: 540-218-2232
fax: -
thoffmann@troutgroup.com http://landosbiopharma.com
 
 • General Corporate Information   
Officers
Tim M. Mayleben - President; Chief Executive Officer
Christopher Garabedian - Chairman of the Board of Director
Patricia L. Bitar - Interim Chief Financial Officer
Fred Callori - Director
Tiago Girao - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 515069102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 40.26
Most Recent Split Date: (:1)
Beta: 1.49
Market Capitalization: $27.82 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.37 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.40 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.45
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 2.63%
vs. Previous Quarter: 28.85%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -51.46
12/31/21 - -40.77
09/30/21 - -48.10
ROA
03/31/22 - -44.14
12/31/21 - -36.04
09/30/21 - -32.61
Current Ratio
03/31/22 - 4.99
12/31/21 - 5.55
09/30/21 - 9.40
Quick Ratio
03/31/22 - 4.99
12/31/21 - 5.55
09/30/21 - 9.40
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -241.49
12/31/21 - -213.46
09/30/21 - -164.81
Book Value
03/31/22 - 1.54
12/31/21 - 1.90
09/30/21 - 2.34
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©